newsfilter
← Latest News
Business Wire·

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

DM199 Preeclampsia Phase 2 Investigator-Sponsored Trial (IST) Part 1a Expansion Cohort Enrolling, Updated Dataset Expected 2Q 2026 ReMEDy2 Phase 2/3 AIS Trial of DM199 Surpassed 70% of Required Interim Enrollment;